Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients

Acurx Pharmaceuticals, Inc.

Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.
Q4 net loss $3.3M ($0.28/share) vs $2.6M ($0.26); FY net loss $12.1M ($1.12) vs $12.7M ($1.49).
R&D expense FY2022 $4.8M (up from $2.0M) due to Phase 2b costs; G&A $7.3M (down from $10.8M).
Phase 2b CDI trial has enrolled 25 of 36 patients needed for IDMC interim review; IDMC may recommend early termination or continue enrollment.
Non-dilutive grant application for $11.3M for ACX-375 (MRSA) in final round; decision expected in April 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.